CN117567478B - 喜树碱类化合物及其制备方法和应用 - Google Patents

喜树碱类化合物及其制备方法和应用 Download PDF

Info

Publication number
CN117567478B
CN117567478B CN202311518671.2A CN202311518671A CN117567478B CN 117567478 B CN117567478 B CN 117567478B CN 202311518671 A CN202311518671 A CN 202311518671A CN 117567478 B CN117567478 B CN 117567478B
Authority
CN
China
Prior art keywords
compound
reaction
formula
mobile phase
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202311518671.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN117567478A (zh
Inventor
田强
张毅涛
缪羽
王波
叶健
汪小蓓
李德亮
李芬
宋宏梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN117567478A publication Critical patent/CN117567478A/zh
Application granted granted Critical
Publication of CN117567478B publication Critical patent/CN117567478B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202311518671.2A 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用 Active CN117567478B (zh)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
CN2021101599566 2021-02-05
CN202110159956 2021-02-05
CN2021105333044 2021-05-17
CN202110533304 2021-05-17
CN202110718245 2021-06-28
CN2021107182458 2021-06-28
CN202110936768 2021-08-16
CN202110936768X 2021-08-16
CN2021113553309 2021-11-16
CN202111355330 2021-11-16
CN202280008418.XA CN116829561B (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用
PCT/CN2022/074328 WO2022166762A1 (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280008418.XA Division CN116829561B (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN117567478A CN117567478A (zh) 2024-02-20
CN117567478B true CN117567478B (zh) 2025-03-21

Family

ID=82741966

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311518671.2A Active CN117567478B (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用
CN202280008418.XA Active CN116829561B (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用
CN202510232225.8A Pending CN120058723A (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202280008418.XA Active CN116829561B (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用
CN202510232225.8A Pending CN120058723A (zh) 2021-02-05 2022-01-27 喜树碱类化合物及其制备方法和应用

Country Status (9)

Country Link
US (3) US20240158410A1 (enExample)
EP (3) EP4613335A3 (enExample)
JP (3) JP7821188B2 (enExample)
KR (3) KR20250119655A (enExample)
CN (3) CN117567478B (enExample)
AU (1) AU2022216696A1 (enExample)
CA (1) CA3209426A1 (enExample)
MX (1) MX2023008716A (enExample)
WO (1) WO2022166762A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4516357T3 (da) 2020-09-30 2026-04-27 Duality Biologics Suzhou Co Ltd Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf
EP4227310A4 (en) * 2020-10-12 2024-11-06 Sichuan Baili Pharmaceutical Co. Ltd. CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE THEREOF
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
JP2024532768A (ja) * 2021-08-19 2024-09-10 ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド カンプトテシン誘導体、その薬物組成物およびその応用
US20250059143A1 (en) * 2021-10-26 2025-02-20 Shanghai Best-Link Bioscience, Llc Camptothecin derivative intermediate, and preparation method therefor and use thereof
JP7767613B2 (ja) 2021-11-15 2025-11-11 システィミューン，インコーポレイテッド 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
TW202344252A (zh) * 2022-05-09 2023-11-16 大陸商同宜醫藥（蘇州）有限公司 一種喜樹鹼衍生物，基於其的抗體－藥物偶聯物和藥物組成物，及其應用
JP2025515988A (ja) 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
WO2024012566A2 (en) 2022-07-15 2024-01-18 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
EP4562051A1 (en) * 2022-07-26 2025-06-04 Immunome, Inc. Immunoconjugates and methods
CN120225528A (zh) * 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
CN121064211A (zh) * 2022-09-09 2025-12-05 杭州爱科瑞思生物医药有限公司 喜树碱-7-乙基胺衍生物及其制备方法和应用
AU2023349279A1 (en) * 2022-09-30 2025-05-15 Beone Medicines I Gmbh Ligand-drug conjugate of exatecan analogue, and medical use thereof
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2024114318A1 (zh) * 2022-11-29 2024-06-06 四川科伦博泰生物医药股份有限公司 药物连接子化合物及其制备方法和用途
CN116870187A (zh) * 2022-12-29 2023-10-13 杭州爱科瑞思生物医药有限公司 N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物
CN116712563A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-卤代烷基取代的喜树碱衍生物的抗体偶联药物
CN116712562A (zh) * 2022-12-29 2023-09-08 杭州爱科瑞思生物医药有限公司 N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物
WO2024158996A2 (en) * 2023-01-25 2024-08-02 Zeno Management, Inc. Immunoconjugates and methods
IL322897A (en) * 2023-02-23 2025-10-01 Phrontline Biopharma Hangzhou Co Ltd Camptothecin derivatives and conjugates, methods for their preparation and medical uses
KR20250152646A (ko) * 2023-03-01 2025-10-23 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인데노[1,2-b]퀴놀린-10,13-디온 유도체의 제조 방법
EP4692091A1 (en) * 2023-04-07 2026-02-11 Changchun Genescience Pharmaceutical Co., Ltd. Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof
CN116478051B (zh) * 2023-04-13 2024-06-21 戊言医药科技（上海）有限公司 一种贝洛替康盐酸盐及其关键中间体的制备方法
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN120826405A (zh) * 2023-05-04 2025-10-21 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
CN117417346B (zh) * 2023-09-11 2025-07-25 常州合全药业有限公司 喜树碱类衍生物的制备方法
KR20250059577A (ko) 2023-10-24 2025-05-07 삼성디스플레이 주식회사 표시 장치
CN122161833A (zh) * 2023-11-15 2026-06-05 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
CN120058720A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用
CN120058721A (zh) * 2024-01-08 2025-05-30 杭州爱科瑞思生物医药有限公司 7-氟烷基取代的喜树碱衍生物的制备及其应用
WO2025162049A1 (zh) * 2024-02-02 2025-08-07 长春金赛药业有限责任公司 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用
WO2025242090A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 喜树碱衍生物及其中间体的制备方法
WO2026046398A1 (en) * 2024-08-30 2026-03-05 Hansoh Bio Llc Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof
WO2026158370A1 (zh) * 2025-01-24 2026-07-30 四川科伦博泰生物医药股份有限公司 具有生物活性的化合物的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495432A1 (en) * 1991-01-16 1992-07-22 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
CN1158334A (zh) * 1995-12-28 1997-09-03 田边制药株式会社 喜树碱衍生物
WO2019114666A1 (zh) * 2017-12-15 2019-06-20 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
WO2020219287A1 (en) * 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives
CN111936169A (zh) * 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
DE69635560T2 (de) * 1995-06-21 2006-08-17 Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) Camptothecinanaloge, Verfahren zur ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
CN100408582C (zh) * 2004-02-12 2008-08-06 中国人民解放军第二军医大学 高喜树碱类化合物及其制备方法和用途
EP3442979A4 (en) * 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
CN110891942B (zh) * 2017-07-14 2022-06-07 四川科伦博泰生物医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
TWI920652B (zh) * 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
UA130338C2 (uk) * 2018-09-26 2026-01-28 Джянгсу Хенгруй Медісін Ко., Лтд. Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
JP7408646B2 (ja) * 2018-09-30 2024-01-05 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途
KR20240104214A (ko) * 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체
CN110357897A (zh) * 2019-07-26 2019-10-22 上海健康医学院 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用
US20230101735A1 (en) * 2020-01-22 2023-03-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-trop-2 antidody-exatecan analog conjugate and medical use thereof
BR112022024930A2 (pt) * 2020-06-08 2022-12-27 Baili Bio Chengdu Pharmaceutical Co Ltd Fármaco de camptotecina possuindo unidade de conexão hidrofílica de alta estabilidade e conjugado do mesmo
WO2022078259A1 (zh) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 一种氘代的喜树碱衍生物及其抗体药物偶联物
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
US20240252665A1 (en) * 2021-06-02 2024-08-01 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Chemical coupling linker and use thereof
MX2023012920A (es) * 2021-06-02 2023-11-13 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-farmaco y metodo de preparacion y uso del mismo.
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CN117567487A (zh) * 2023-11-27 2024-02-20 金宏气体股份有限公司 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495432A1 (en) * 1991-01-16 1992-07-22 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
CN1158334A (zh) * 1995-12-28 1997-09-03 田边制药株式会社 喜树碱衍生物
WO2019114666A1 (zh) * 2017-12-15 2019-06-20 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111936169A (zh) * 2018-04-06 2020-11-13 西雅图遗传学公司 喜树碱肽缀合物
WO2020219287A1 (en) * 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物

Also Published As

Publication number Publication date
EP4628165A2 (en) 2025-10-08
US20260152510A1 (en) 2026-06-04
JP2025160318A (ja) 2025-10-22
CN120058723A (zh) 2025-05-30
US20240158410A1 (en) 2024-05-16
CN116829561B (zh) 2026-07-31
US20250346606A1 (en) 2025-11-13
MX2023008716A (es) 2023-08-02
EP4613335A2 (en) 2025-09-10
KR20250120438A (ko) 2025-08-08
CN116829561A (zh) 2023-09-29
EP4613335A3 (en) 2025-12-10
CN117567478A (zh) 2024-02-20
EP4289851A4 (en) 2025-10-15
JP7821188B2 (ja) 2026-02-26
KR20230142710A (ko) 2023-10-11
EP4289851A1 (en) 2023-12-13
KR20250119655A (ko) 2025-08-07
EP4628165A3 (en) 2026-03-11
JP2025160317A (ja) 2025-10-22
JP2024506819A (ja) 2024-02-15
CA3209426A1 (en) 2022-08-11
AU2022216696A1 (en) 2023-08-17
WO2022166762A1 (zh) 2022-08-11

Similar Documents

Publication Publication Date Title
CN120058723A (zh) 喜树碱类化合物及其制备方法和应用
CN116249683B (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
JP2025515988A (ja) カンプトテシン化合物、その調製方法及びその使用
CN116157400B (zh) 杂环类衍生物及其制备方法和用途
CN116113416B (zh) 四环类衍生物、其制备方法和其医药上的用途
CN116406363B (zh) 四环类衍生物、其制备方法及其医药上的用途
CN112745335A (zh) 一种三并杂环化合物及其用途
JP7538803B2 (ja) イミダゾキノリンアミン誘導体、医薬組成物、その使用
CN112300153A (zh) 一种杂环化合物、药物组合物和用途
WO2025214344A1 (zh) 一种kras抑制剂及其在药学上的应用
WO2025036489A1 (zh) 一种氰基芳香环衍生物及其在医药上的应用
WO2013091507A1 (zh) 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
CN113929681A (zh) 四环类衍生物及其制备方法和用途
JP2024508426A (ja) 免疫調節物質及び免疫調節物質コンジュゲート
EP3216799A1 (en) New type of cytidine derivative dimer and application thereof
HK40101679A (en) Camptothecin compound, preparation method therefor, and application thereof
HK40101679B (en) Camptothecin compound, preparation method therefor, and application thereof
JP2024517867A (ja) Ｗｄｒ５阻害剤およびモジュレーター
EP4219453A1 (en) Pyrazole compound and preparation method therefor and use thereof
CN120858098A (zh) 稠环化合物及其制备方法和应用
CN112996784B (zh) 吲哚衍生物及其在医药上的应用
Vitkovska et al. Appendix IV–MACROCYCLIC TUBULIN POLYMERIZATION INHIBITORS AS ANTICANCER AGENTS
WO2026098309A1 (zh) 多并环类化合物及其制备方法和用途
HK40068190A (en) Imidazoquinoline amine derivatives, pharmaceutical compositions and use thereof
HK40090213A (en) Benzothiazolyl biaryl compound, and preparation method and use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101679

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant